Conatus Pharmaceuticals (CNAT) PT Lowered to $15.00 at HC Wainwright

Conatus Pharmaceuticals (NASDAQ:CNAT) had its target price trimmed by HC Wainwright from $17.00 to $15.00 in a research note released on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.

CNAT has been the subject of a number of other reports. Zacks Investment Research cut shares of Conatus Pharmaceuticals from a hold rating to a sell rating in a research report on Monday, January 22nd. Oppenheimer reaffirmed a buy rating on shares of Conatus Pharmaceuticals in a research report on Thursday, March 22nd. ValuEngine upgraded shares of Conatus Pharmaceuticals from a sell rating to a hold rating in a report on Friday, March 2nd. Roth Capital initiated coverage on shares of Conatus Pharmaceuticals in a report on Thursday, February 8th. They issued a buy rating and a $20.00 price objective on the stock. Finally, S&P Equity Research boosted their price objective on shares of Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $12.00.

How to Become a New Pot Stock Millionaire

Shares of Conatus Pharmaceuticals stock opened at $4.03 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.82 and a quick ratio of 2.82. Conatus Pharmaceuticals has a twelve month low of $3.85 and a twelve month high of $9.40. The firm has a market cap of $121.14, a P/E ratio of -6.61 and a beta of 1.16.

Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its quarterly earnings results on Wednesday, March 7th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.02. Conatus Pharmaceuticals had a negative net margin of 49.17% and a negative return on equity of 61.58%. The firm had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $9.60 million. sell-side analysts expect that Conatus Pharmaceuticals will post -0.71 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in Conatus Pharmaceuticals by 3,098.0% in the 3rd quarter. Wells Fargo & Company MN now owns 19,188 shares of the biotechnology company’s stock worth $105,000 after buying an additional 18,588 shares in the last quarter. New York State Common Retirement Fund lifted its holdings in Conatus Pharmaceuticals by 156.4% in the 3rd quarter. New York State Common Retirement Fund now owns 24,100 shares of the biotechnology company’s stock worth $132,000 after buying an additional 14,700 shares in the last quarter. Stone Ridge Asset Management LLC acquired a new position in Conatus Pharmaceuticals in the 4th quarter worth $143,000. California State Teachers Retirement System acquired a new position in Conatus Pharmaceuticals in the 2nd quarter worth $261,000. Finally, Macquarie Group Ltd. acquired a new position in Conatus Pharmaceuticals in the 3rd quarter worth $330,000. Hedge funds and other institutional investors own 39.49% of the company’s stock.

WARNING: This piece was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3341138/conatus-pharmaceuticals-cnat-pt-lowered-to-15-00-at-hc-wainwright-2.html.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Analyst Recommendations for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pascal Coin  Hits Market Cap of $22.17 Million
Pascal Coin Hits Market Cap of $22.17 Million
Ormeus Coin  Reaches 1-Day Volume of $7.12 Million
Ormeus Coin Reaches 1-Day Volume of $7.12 Million
Cross Timbers Royalty Trust  Getting Somewhat Favorable News Coverage, Report Finds
Cross Timbers Royalty Trust Getting Somewhat Favorable News Coverage, Report Finds
Somewhat Favorable News Coverage Somewhat Unlikely to Affect MEI Pharma  Stock Price
Somewhat Favorable News Coverage Somewhat Unlikely to Affect MEI Pharma Stock Price
United-Guardian  Earning Somewhat Favorable Media Coverage, Study Shows
United-Guardian Earning Somewhat Favorable Media Coverage, Study Shows
Fresenius Medical Care  Given a €93.00 Price Target at Nord/LB
Fresenius Medical Care Given a €93.00 Price Target at Nord/LB


© 2006-2018 Ticker Report. Google+.